Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Holding ASND?
Track your performance easily
ASND Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$111.09 - $161.00
Previous Close$136.38
Volume690.27K
Average Volume (3M)457.31K
Market Cap
$8.15B
Enterprise Value$8.41B
Total Cash (Recent Filing)€399.44M
Total Debt (Recent Filing)€644.26M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Apr 02, 2025EPS Estimate
-$1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.10
Shares Outstanding56,614,385
10 Day Avg. Volume545,438
30 Day Avg. Volume457,312
Standard Deviation0.12
R-Squared0.09
Alpha0.00136
Financial Highlights & Ratios
Price to Book (P/B)-53.07
Price to Sales (P/S)25.98
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$193.69Price Target Upside42.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Ascendis Pharma News
PremiumCompany Announcements
Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk
PremiumCompany Announcements
Ascendis Pharma’s TransCon hGH Receives FDA Review for Adult Use
PremiumCompany Announcements
Ascendis Pharma Reviews Share Structure and Capital StrategyBulls Say, Bears Say
Bulls Say
Collaboration And Product DevelopmentThe new collaboration with Novo on metabolic/CV diseases adds substantial potential, starting with a once-monthly GLP-1 product candidate for obesity and diabetes.
Growth Hormone Market TrendsManagement remains optimistic that the growth hormone market is shifting away from the daily formulations to long-acting ones.
Product Launch And Market PositionYorvipath will become the only available PTH therapy for approximately 200,000 HP patients worldwide, providing a better treatment option with a superior clinical profile.
Bears Say
Management And ExecutionRevenue guidance revision and sales performance highlight concerns over management's execution, posing a risk to the US Yorvipath launch.
Market CompetitionThe emergence of infigratinib as an oral competitor for achondroplasia suggests it might surpass Skytrofa due to its more convenient dosing profile.
Sales PerformanceSkytrofa sales reported at €47.2M, falling short of analyst expectations, indicating potential challenges in market demand or pricing strategy.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $111.09 and its highest was $161.00 in the past 12 months.
What is Ascendis Pharma’s market cap?
Currently, no data Available
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Apr 02, 2025 which is in 101 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Nov 14, 2024. The company reported -$1.794 earnings per share for the quarter, missing the consensus estimate of -$1.632 by -$0.162.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is -$1.35.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 60,231,483 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$1.794 in its last earnings report, missing expectations of -$1.632. Following the earnings report the stock price went up 1.794%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Among the largest hedge funds holding Ascendis Pharma’s share is RA Capital Management. It holds Ascendis Pharma’s shares valued at 1B.
---
Ascendis Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$193.69 (42.02% Upside)
$193.69 (42.02% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 113.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
32.04%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
---
ASND Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with strong progress in product development and market positioning, especially for SKYTROFA and YORVIPATH. The collaboration with Novo Nordisk highlights growth potential, while financial metrics indicate robust health. However, challenges remain, including revenue adjustments for SKYTROFA and uncertainties in the NATPARA transition.Read More>---
ASND Stock 12 Month Forecast
Average Price Target
$193.69
▲(42.02% Upside)
Technical Analysis
Best Analysts Covering ASND
1 Year
1 Year Success Rate
24/28 ratings generated profit
1 Year Average Return
+24.34%
reiterated a buy rating 6 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +24.34% per trade.
---